Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Matsuda H, Hara M, Iwakami SI, Takahashi K. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib. BMJ Case Rep 2021;14:14/4/e240295. [PMID: 33906872 PMCID: PMC8088238 DOI: 10.1136/bcr-2020-240295] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open

For:	Matsuda H, Hara M, Iwakami SI, Takahashi K. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib. BMJ Case Rep 2021;14:14/4/e240295. [PMID: 33906872 PMCID: PMC8088238 DOI: 10.1136/bcr-2020-240295] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open

Number

Cited by Other Article(s)

Baba K, Goto Y. Lorlatinib as a treatment for ALK-positive lung cancer. Future Oncol 2022;18:2745-2766. [PMID: 35787143 DOI: 10.2217/fon-2022-0184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open